scispace - formally typeset
Open AccessJournal ArticleDOI

Leptin-Induced Sympathetic Nerve Activation: Signaling Mechanisms and Cardiovascular Consequences in Obesity.

TLDR
It is demonstrated that leptin plays a physiological role in maintaining sympathetic tone and blood pressure, and further suggest that hyperleptinemia may contribute to the elevated blood pressure associated with obesity.
Abstract
Obesity increases cardiovascular morbidity and mortality in part by inducing hypertension. One factor linking excess fat mass to cardiovascular diseases may be the sympathetic cardiovascular actions of leptin. Initial studies of leptin showed it regulates appetite and enhances energy expenditure by activating sympathetic nerve activity (SNA) to thermogenic brown adipose tissue. Further study, however, demonstrated leptin also causes sympathetic excitation to the kidney that, in turn, increases arterial pressure. In animal studies, elevating circulating leptin levels increased arterial pressure. Moreover, mice with diet-induced obesity have a preserved arterial pressure response to leptin despite the resistance to the metabolic action of leptin and these mice have elevated baseline arterial pressure. Conversely, severely obese, but leptin-deficient, mice and humans display low sympathetic tone and decreased blood pressure. Together, these findings demonstrate that leptin plays a physiological role in maintaining sympathetic tone and blood pressure, and further suggest that hyperleptinemia may contribute to the elevated blood pressure associated with obesity. Consistent with this selectivity in leptin resistance, mounting evidence suggests that the sympathetic nervous system subserving different tissues is differentially controlled by leptin. For instance, different molecular signaling mechanisms are engaged by the leptin receptor to control the regional sympathetic nerve activity. Understanding the mechanisms by which leptin controls the sympathetic nervous system will provide insight into the cardiovascular complications of obesity.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Change in sympathetic nerve firing pattern associated with dietary weight loss in the metabolic syndrome

TL;DR: Hypocaloric diet decreased sympathetic activity and improved hemodynamic and metabolic parameters, and sympathoinhibition associated with weight loss involves marked changes, not only in the rate but also in the firing pattern of active vasoconstrictive fibers.
Journal ArticleDOI

Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity.

TL;DR: Leptin locally produced in the heart could participate in the fibrosis observed in HFD by affecting collagen turnover, andCollagen synthesis induced by leptin seems to be mediated by the production of galectin-3, TGF-&bgr; and CTGF through oxidative stress increased by activation of mTOR pathway.
Journal ArticleDOI

DNA methylation of leptin and adiponectin promoters in children is reduced by the combined presence of obesity and insulin resistance

TL;DR: Observations sustain the hypothesis that epigenetic modifications might underpin the development of obesity and related metabolic disorders and validate the use of blood leukocytes and MS-PCR as a reliable and affordable methodology for the identification of epigenetic modification that could be used as molecular markers to predict and follow up the physiological changes associated with obesity and insulin resistance.
Journal ArticleDOI

Daily rhythms of plasma melatonin, but not plasma leptin or leptin mRNA, vary between lean, obese and type 2 diabetic men.

TL;DR: Altered plasma melatonin rhythms in weight-matched T2 DM and non-diabetic individuals supports a possible role of melatonin in T2DM aetiology, while post-hoc analysis revealed no significant pair-wise effects of group on leptin mRNA expression.
Journal ArticleDOI

The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity.

TL;DR: Data suggest that an SGLT2 inhibitor decreases BP by normalizing the circadian rhythms of BP and SNA, which may be the source of its beneficial effects on CV outcome in high-risk patients with type 2 diabetes.
Related Papers (5)